

Pipeline of Next-Generation Single- and Dual-Payload ADCs

	PROGRAM	MODALITY/TARGET	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1/1B	PHASE 2	PHASE 3/ REGISTRATIONAL	MILESTONES
WHOLLY-OWNED PROGRAMS	STRO-004	Tissue Factor ADC	Solid Tumors						Initial Phase 1 data expected mid-2026
	STRO-006	Integrin $\alpha\beta 6$	Solid Tumors						IND submission expected 2026
	STRO-227	PTK7 Dual-Payload ADC	Solid Tumors						IND submission expected 2026
	STRO-00Y	Dual-Payload ADC	Solid Tumors						
PARTNERED PROGRAMS	VAX-31 <small>VAXCYTE part of kemrad</small>	31-Valent Conjugate Vaccine	Invasive Pneumococcal Disease						
	VAX-24 <small>VAXCYTE part of kemrad</small>	24-Valent Conjugate Vaccine	Invasive Pneumococcal Disease						
	ASP2998 <small>astellas</small>	TROP2-targeted Immunostimulatory ADC (iADC)	Cancers						Entered the clinic 1Q 2026; dosing underway
	Undisclosed Program <small>astellas</small>	iADC	Cancers						